|
1
|
Stratton MR: Exploring the genomes of
cancer cells: Progress and promise. Science. 331:1553–1558. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Eifert C and Powers RS: From cancer
genomes to oncogenic drivers, tumour dependencies and therapeutic
targets. Nat Rev Cancer. 12:572–578. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Davis MI, Hunt JP, Herrgard S, Ciceri P,
Wodicka LM, Pallares G, Hocker M, Treiber DK and Zarrinkar PP:
Comprehensive analysis of kinase inhibitor selectivity. Nat
Biotechnol. 29:1046–1051. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
van der Kuip H, Mürdter TE, Sonnenberg M,
McClellan M, Gutzeit S, Gerteis A, Simon W, Fritz P and Aulitzky
WE: Short term culture of breast cancer tissues to study the
activity of the anticancer drug taxol in an intact tumor
environment. BMC Cancer. 6:862006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dean JL, McClendon AK, Hickey TE, Butler
LM, Tilley WD, Witkiewicz AK and Knudsen ES: Therapeutic response
to CDK4/6 inhibition in breast cancer defined by ex vivo analyses
of human tumors. Cell Cycle. 11:2756–2761. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Séveno C, Loussouarn D, Bréchet S, Campone
M, Juin P and Barillé-Nion S: γ-Secretase inhibition promotes cell
death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737
in human breast cancer cells. Breast Cancer Res. 14:R962012.
View Article : Google Scholar
|
|
7
|
Grosso SH, Katayama ML, Roela RA, Nonogaki
S, Soares FA, Brentani H, Lima L, Folgueira MA, Waitzberg AF,
Pasini FS, et al: Breast cancer tissue slices as a model for
evaluation of response to rapamycin. Cell Tissue Res. 352:671–684.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Holliday DL, Moss MA, Pollock S, Lane S,
Shaaban AM, Millican-Slater R, Nash C, Hanby AM and Speirs V: The
practicalities of using tissue slices as preclinical organotypic
breast cancer models. J Clin Pathol. 66:253–255. 2013. View Article : Google Scholar
|
|
9
|
Pennington K, Chu QD, Curiel DT, Li BD and
Mathis JM: The utility of a tissue slice model system to determine
breast cancer infectivity by oncolytic adenoviruses. J Surg Res.
163:270–275. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Godin C, Dupont S, Ezzoukhry Z, Louandre
C, Chatelain D, Henaut L, Sabbagh C, Regimbeau JM, Maziere JC,
Barbare JC, et al: Heterogeneous sensitivity of hepatocellular
carcinoma to sorafenib revealed by the short-term culture of tumor
fragments. Anticancer Res. 33:1415–1420. 2013.PubMed/NCBI
|
|
11
|
Gerlach MM, Merz F, Wichmann G, Kubick C,
Wittekind C, Lordick F, Dietz A and Bechmann I: Slice cultures from
head and neck squamous cell carcinoma: A novel test system for drug
susceptibility and mechanisms of resistance. Br J Cancer.
110:479–488. 2014. View Article : Google Scholar :
|
|
12
|
Peria M, Donnadieu J, Racz C, Ikoli JF,
Galmiche A, Chauffert B and Page C: Evaluation of individual
sensitivity of head and neck squamous cell carcinoma to cetuximab
by short-term culture of tumor slices. Head Neck. May 20–2015.Epub
ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Micel LN, Tentler JJ, Tan AC, Selby HM,
Brunkow KL, Robertson KM, Davis SL, Klauck PJ, Pitts TM, Gangolli
E, et al: Antitumor activity of the MEK inhibitor TAK-733 against
melanoma cell lines and patient-derived tumor explants. Mol Cancer
Ther. 14:317–325. 2015. View Article : Google Scholar :
|
|
14
|
Vaira V, Fedele G, Pyne S, Fasoli E, Zadra
G, Bailey D, Snyder E, Faversani A, Coggi G, Flavin R, et al:
Preclinical model of organotypic culture for pharmacodynamic
profiling of human tumors. Proc Natl Acad Sci USA. 107:8352–8356.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Corben AD, Uddin MM, Crawford B, Farooq M,
Modi S, Gerecitano J, Chiosis G and Alpaugh ML: Ex vivo treatment
response of primary tumors and/or associated metastases for
preclinical and clinical development of therapeutics. J Vis Exp.
92:e521572014.PubMed/NCBI
|
|
16
|
Merz F, Gaunitz F, Dehghani F, Renner C,
Meixensberger J, Gutenberg A, Giese A, Schopow K, Hellwig C,
Schäfer M, et al: Organotypic slice cultures of human glioblastoma
reveal different susceptibilities to treatments. Neuro-oncol.
15:670–681. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nakasone ES, Askautrud HA, Kees T, Park
JH, Plaks V, Ewald AJ, Fein M, Rasch MG, Tan YX, Qiu J, et al:
Imaging tumor-stroma interactions during chemotherapy reveals
contributions of the microenvironment to resistance. Cancer Cell.
21:488–503. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Correia AL and Bissell MJ: The tumor
microenvironment is a dominant force in multidrug resistance. Drug
Resist Updat. 15:39–49. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gomes LR, Vessoni AT and Menck CF:
Three-dimensional microenvironment confers enhanced sensitivity to
doxorubicin by reducing p53-dependent induction of autophagy.
Oncogene. 34:5329–5340. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sharma SV, Haber DA and Settleman J: Cell
line-based platforms to evaluate the therapeutic efficacy of
candidate anticancer agents. Nat Rev Cancer. 10:241–253. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Daniel VC, Marchionni L, Hierman JS,
Rhodes JT, Devereux WL, Rudin CM, Yung R, Parmigiani G, Dorsch M,
Peacock CD, et al: A primary xenograft model of small-cell lung
cancer reveals irreversible changes in gene expression imposed by
culture in vitro. Cancer Res. 69:3364–3373. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Begley CG and Ellis LM: Drug development:
Raise standards for preclinical cancer research. Nature.
483:531–533. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lao Z, Kelly CJ, Yang XY, Jenkins WT,
Toorens E, Ganguly T, Evans SM and Koch CJ: Improved methods to
generate spheroid cultures from tumor cells, tumor cells &
fibroblasts or tumor-Fragments: Microenvironment, microvesicles and
miRNA. PLoS One. 10:e01338952015. View Article : Google Scholar :
|
|
24
|
van de Wetering M, Francies HE, Francis
JM, Bounova G, Iorio F, Pronk A, van Houdt W, van Gorp J,
Taylor-Weiner A, Kester L, et al: Prospective derivation of a
living organoid biobank of colorectal cancer patients. Cell.
161:933–945. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
DeRose YS, Wang G, Lin YC, Bernard PS,
Buys SS, Ebbert MT, Factor R, Matsen C, Milash BA, Nelson E, et al:
Tumor grafts derived from women with breast cancer authentically
reflect tumor pathology, growth, metastasis and disease outcomes.
Nat Med. 17:1514–1520. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gould SE, Junttila MR and de Sauvage FJ:
Translational value of mouse models in oncology drug development.
Nat Med. 21:431–439. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cassidy JW, Caldas C and Bruna A:
Maintaining tumor heterogeneity in patient-derived tumor
xenografts. Cancer Res. 75:2963–2968. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Eirew P, Steif A, Khattra J, Ha G, Yap D,
Farahani H, Gelmon K, Chia S, Mar C, Wan A, et al: Dynamics of
genomic clones in breast cancer patient xenografts at single-cell
resolution. Nature. 518:422–426. 2015. View Article : Google Scholar
|
|
29
|
Wulkersdorfer B, Zeitlinger M and Schmid
M: Pharmacokinetic aspects of vascular endothelial growth factor
tyrosine kinase inhibitors. Clin Pharmacokinet. Jul 23–2015.Epub
ahead of print. PubMed/NCBI
|
|
30
|
Jørgensen JT: Clinical application of
companion diagnostics. Trends Mol Med. 21:405–407. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sohal DP, Rini BI, Khorana AA, Dreicer R,
Abraham J, Procop GW, Saunthararajah Y, Pennell NA, Stevenson JP,
Pelley R, et al: Prospective clinical study of precision oncology
in solid tumors. J Natl Cancer Inst. 108:djv3322015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
André F, Bachelot T, Commo F, Campone M,
Arnedos M, Dieras V, Lacroix-Triki M, Lacroix L, Cohen P, Gentien
D, et al: Comparative genomic hybridisation array and DNA
sequencing to direct treatment of metastatic breast cancer: A
multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol.
15:267–274. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hidalgo M, Bruckheimer E, Rajeshkumar NV,
Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, Strawn S, Wick
MJ, Martell J and Sidransky D: A pilot clinical study of treatment
guided by personalized tumorgrafts in patients with advanced
cancer. Mol Cancer Ther. 10:1311–1316. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gao H, Korn JM, Ferretti S, Monahan JE,
Wang Y, Singh M, Zhang C, Schnell C, Yang G, Zhang Y, et al:
High-throughput screening using patient-derived tumor xenografts to
predict clinical trial drug response. Nat Med. 21:1318–1325. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Clohessy JG and Pandolfi PP: Mouse
hospital and co-clinical trial project - from bench to bedside. Nat
Rev Clin Oncol. 12:491–498. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Reyes DK and Pienta KJ: The biology and
treatment of oligo-metastatic cancer. Oncotarget. 6:8491–8524.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Friedman AA, Letai A, Fisher DE and
Flaherty KT: Precision medicine for cancer with next-generation
functional diagnostics. Nat Rev Cancer. 15:747–756. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Majumder B, Baraneedharan U, Thiyagarajan
S, Radhakrishnan P, Narasimhan H, Dhandapani M, Brijwani N, Pinto
DD, Prasath A, Shanthappa BU, Thayakumar A, Surendran R, Babu GK,
Shenoy AM, Kuriakose MA, Bergthold G, Horowitz P, Loda M, Beroukhim
R, Agarwal S, Sengupta S, Sundaram M and Majumder PK: Predicting
clinical response to anticancer drugs using an ex vivo platform
that captures tumour heterogeneity. Nat Commun. 6:61692015.
View Article : Google Scholar : PubMed/NCBI
|
